NCT03179930 2025-07-23
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
Memorial Sloan Kettering Cancer Center
University of Chicago
Glenmark Specialty S.A.